Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting

Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap

(2020) Arnoud J. Templeton et al.   JOURNAL OF CLINICAL ONCOLOGY

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

(2020) Mercedeh Ghadessi et al.   Orphanet Journal of Rare Diseases

Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study

(2020) Maarten L. Donswijk et al.   BMC CANCER

Outcomes following liver SBRT for metastatic pancreatic cancer.

(2019) Oluwadamilola Temilade Oladeru et al.   JOURNAL OF CLINICAL ONCOLOGY

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

(2019) Andrea Wang-Gillam et al.   EUROPEAN JOURNAL OF CANCER

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Maintenance Strategies in Metastatic Colorectal Cancer

(2019) Mohamad Bassam Sonbol et al.   JAMA Oncology

Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature

(2018) Massimo Ambroggi et al.   SUPPORTIVE CARE IN CANCER

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

(2017) Stéphane Oudard et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.

(2017) David Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

(2015) D. Goldstein et al.   JNCI-Journal of the National Cancer Institute

Developing a national database for metastatic colorectal cancer management: perspectives and challenges

(2013) K. Field et al.   INTERNAL MEDICINE JOURNAL

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

(2011) Katy L Cooper et al.   BMC CANCER

BioGrid Australia facilitates collaborative medical and bioinformatics research across hospitals and medical research institutes by linking data from diverse disease and data types

(2011) Robert B. Merriel et al.   HUMAN MUTATION

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?

(2010) D. Sargent   ONCOLOGIST

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY